Table 6.
Univariate and multivariate analysis of OS predictors in 1: 1 matched groups of men with breast cancer.
| Variables | 5-year OS (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Log Rank χ2 test | P value | HR | 95% CI | P value | ||
| Marital status | 30.037 | <0.0001 | ||||
| Married | 74.5 | Reference | ||||
| Unmarried | 64.8 | 1.519 | 1.315–1.754 | <0.0001 | ||
| Age | 176.879 | <0.0001 | ||||
| <50 | 85.8 | Reference | ||||
| 50–64 | 79.9 | 1.207 | 0.929–1.569 | 0.159 | ||
| ≥65 | 58.0 | 2.965 | 2.332–3.769 | <0.0001 | ||
| Race | 5.568 | 0.135 | ||||
| White | 69.6 | Reference | ||||
| Black | 68.6 | 1.285 | 1.063–1.553 | 0.009 | ||
| Other | 69.5 | 0.835 | 0.547–1.275 | 0.403 | ||
| Residence type | 3.073 | 0.215 | ||||
| Metropolitan | 70.1 | |||||
| Non-metropolitan | 65.0 | |||||
| Histology | 6.614 | 0.037 | ||||
| Ductal | 68.5 | Reference | ||||
| Lobular | 85.7 | 0.747 | 0.183–3.054 | 0.685 | ||
| Others | 76.4 | 0.815 | 0.646–1.028 | 0.084 | ||
| Grade | 28.177 | <0.0001 | ||||
| Well/moderately differentiated | 75.0 | Reference | ||||
| Poorly/undifferentiated | 59.6 | 1.379 | 1.184–1.607 | <0.0001 | ||
| Pathologic T stage | 63.425 | <0.0001 | ||||
| T0–T1 | 84.4 | Reference | ||||
| T2 | 63.2 | 1.971 | 1.516–2.561 | <0.0001 | ||
| T3 | 57.1 | 2.420 | 1.621–3.613 | <0.0001 | ||
| Pathologic N stage | 279.309 | <0.0001 | ||||
| N0 | 81.6 | Reference | ||||
| N1 | 69.9 | 1.588 | 1.310–1.926 | <0.0001 | ||
| N2 | 64.0 | 2.332 | 1.815–2.996 | <0.0001 | ||
| N3 | 59.6 | 2.517 | 1.908–3.319 | <0.0001 | ||
| ER status | 0.656 | 0.720 | ||||
| Negative | 75.1 | |||||
| Positive | 69.5 | |||||
| HER2 status | 9.335 | 0.009 | ||||
| Negative | 72.8 | Reference | ||||
| Positive | 61.3 | 1.557 | 0.882–2.748 | 0.127 | ||
| Surgery | 64.162 | <0.0001 | ||||
| No | 36.9 | Reference | ||||
| Yes | 72.2 | 0.694 | 0.464–1.040 | 0.077 | ||
| Radiation | 0.324 | 0.569 | ||||
| No | 68.1 | Reference | ||||
| Yes | 73.7 | 0.865 | 0.728–1.029 | 0.101 | ||
CI – confidence interval; ER – estrogen receptor; HER2 – human epidermal growth factor receptor 2; HR – hazard ratio; OS – overall survival; PR – progesterone receptor.